Skip to main content

NCT00246233 - A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.

A Double-blind, Placebo-controlled, Randomized Trial to Evaluate the Safety, Tolerability and Efficacy of CONCERTA® (Methylphenidate Hydrochloride) Augmentation of SSRI/SNRI Monotherapy in Adult Patients With Major Depressive Disorder.

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.


CSR Summary

Not Yet Available


Data Specification

Available upon data request approval


Annotated CRF

Available upon data request approval

Product Info

Generic Name
Methylphenidate HCl
Product Name
CONCERTA®
Therapeutic Area
Behaviors and Mental Disorders
Enrollment
145
% Female
64.8%
% White
97.9%
Product Class
Stimulants/ADHD/Anorexiants
Sponsor Protocol Number
42603MDD3001 (CON-CAN-3)
Data Partner
Johnson & Johnson
Condition Studied
Depressive Disorder, Major
Mean/Median Age (Years)
43.8

Supporting Documentation

Analysis Datasets
Clinical Study Report
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Study Phase 
3

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.